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Atrial ﬁbrillation (AF) is the most common arrhythmia and is a
potent risk factor for cardiogenic ischemic stroke especially in
elderly patients. The number of people with AF has been increasing
worldwide as the aged population has increased. It is predicted to
reach 5–16 million in the USA [1] and more than 1 million in Japan in
2030 [2]. A further increase in the number of patients with AF is
expected. Once patients suffer from cardiogenic stroke, the size of
cerebral infarction is usually large, status of disease is mostly severe,
and the prognoses are worse than those in patients with other types
of stroke [3], even in patients with a low CHADS2 or CHA2DS2-VASc
score of 0 or 1. Therefore, early detection of AF is very important to
prevent cardiogenic stroke before starting anticoagulation therapy.
However, it is not always easy to diagnose AF, especially paroxysmal
AF. According to the review of 6319 trans-telephonic electrocar-
diographic strips, asymptomatic paroxysmal AF or ﬂutter (AFL) was
about one fourth of all recordings of paroxysmal AF/AFL in
symptomatic patients, indicating that asymptomatic episodes of
paroxysmal AF/AFL are not rare [4]. On the other hand, viewing from
patients with stroke, AF was detected in 6.8% of patients with acute
ischemic stroke, who had no obvious AF on admission or history of
AF, by continuous electrocardiogram (ECG) monitoring or 24-h
Holter ECG within 25 days (median, 3 days) after onset of stroke [5].
In another report, paroxysmal AF lasting 30 s or longer was found in
16.1% of patients with cryptogenic stroke or transient ischemic
attack (TIA) who did not have previously known AF and the cause of
stroke was undetermined after standard tests including 24-h ECG
monitoring [6].
Present and projected number of patients with AF therefore
may be underestimated. Annual medical checkup including ECG
recording is helpful for the general population to ﬁnd undiagnosedDOI of original article: http://dx.doi.org/10.1016/j.jjcc.2014.08.003
http://dx.doi.org/10.1016/j.jjcc.2014.08.009
0914-5087/ 2014 Published by Elsevier Ltd on behalf of Japanese College of Cardioloasymptomatic AF before onset of stroke. Since incidence of stroke
is comparable between patients with paroxysmal AF and sustained
AF [7], the best effort is needed to detect asymptomatic
paroxysmal AF as the ﬁrst step for the prevention of cardiogenic
stroke in daily clinical practice. Then, anticoagulation therapy
should be considered for these patients.
Several electrical devices such as routine 12-lead ECG at every
visit, 24- or 48-h Holter ECG monitoring, and cardiac event
recorders are currently available for this purpose. In the EMBRACE
trial, additional noninvasive ambulatory ECG monitoring with a
30-day event-triggered recorder after onset of cryptogenic stroke
increased the detection rate of AF 5-fold, as compared with the
standard practice of 24-h ECG monitoring [6]. However, as most
physicians have experienced, these devices cannot perfectly
identify paroxysmal AF especially in outpatient clinics. In that
case, biomarkers would be helpful to suspect an existence of AF
during the blind time without electrical recording.
Usefulness of B-type natriuretic peptide for the detection of
atrial ﬁbrillation
The report by Kara et al. focused on the association between the
level of B-type natriuretic peptide (BNP) and incidence of new-
onset AF in the general population without known heart disease,
prior stroke, or preexisting AF [8]. The authors demonstrated that
elevated levels of BNP were useful as a predictive maker of incident
AF, independent of traditional risk factors of AF. In addition, the
authors showed that the general cut-off level of BNP to identify the
subjects with incident AF was 35 pg/mL and gender-speciﬁc
thresholds were 31 pg/mL for males and 45 pg/mL for females in
the general population [8]. Since the distribution of plasma BNP
levels differs by gender and age [9,10], the results of this study
using gender-speciﬁc thresholds of BNP are valuable [8].
Brain natriuretic peptide (BNP) was ﬁrstly discovered in porcine
brain [11]. Since BNP was found to be released from not only brain
but also ventricular myocardium [12], the term ‘‘B-type natriuretic
peptide’’ has also been used frequently in many manuscripts. BNP
is secreted in response to increased ventricular wall stretch [12]
and plasma BNP levels express the degree of myocardial overload.
Therefore, circulating BNP levels are mainly measured for the
diagnosis and management of heart failure in various clinical
situations [13]. Recently, N-terminal pro-BNP (NT-pro-BNP) has
also been used for the same purpose in the clinical setting, which isgy. Open access under CC BY-NC-ND license.
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in the process of secreting BNP.
BNP is released from both ventricular and atrial myocardium.
Since AF is associated with signiﬁcantly higher BNP levels even in
patients without heart failure [14,15], the measurement of BNP as
a screening of myocardial burden would be reasonable to suspect
an existence of asymptomatic AF or to identify high-risk subjects
for incident AF in future. In the study with patients after acute
ischemic stroke, median value of BNP was 186.6 pg/mL in those
with new-onset AF, whereas it was 35.2 pg/mL in those without
incident AF. The cut-off level of BNP to distinguish patients with
new-onset AF was 65.0 pg/mL [5]. On the other hand, in the present
study with a general healthy population, median values of BNP
were 33.2 pg/mL in subjects with new-onset AF and 16.9 pg/mL in
those without incident AF [8]. These values are lower in a
population-based study [8] than those in a patient-based study [5].
In the results from our study, mean plasma BNP levels in patients
with sustained AF but without heart failure was 134 pg/mL [15].
Although median values of BNP were signiﬁcantly different
between the groups with and without new-onset AF, distribution
of BNP levels in both groups was widely overlapping in this study
[8]. It should be known what characteristics or diseases were
included in the subjects with high BNP levels but without new-
onset AF, and in subjects with low BNP levels but with incident AF.
For this question, the authors described that subjects with high
BNP levels but without incident AF were younger, less obese, and
lower frequency of males and hypertension compared to those
with incident AF. Conversely, subjects with incident AF despite low
BNP levels were older, more obese, and had a higher frequency of
hypertension compared to those without incident AF [8]. These
results are reasonable and consistent with the knowledge of
traditional risk factors of AF. In general, dilatation of left atrium in
echocardiography and existence of atrial premature complex also
provide important information in suspected asymptomatic AF.
Another interesting report was published in 2010 [16]. Predictive
ability of biomarkers for incident AF was evaluated by multivariate
analyses in the study. A total of 3120 Framingham cohort
participants (58.4 years, 54% female) were followed up for 9.7 years
and 10 biomarkers including BNP, N-terminal proatrial natriuretic
peptide, inﬂammatory markers (C-reactive protein and ﬁbrinogen),
oxidative stress (homocysteine), the renin-angiotensin-aldosterone
system (renin and aldosterone), thrombosis, and endothelial
function (D-dimer and plasminogen activator inhibitor type 1),
and microvascular damage (urinary albumin excretion) were related
to incident AF. In these variables, log-transformed BNP (hazard ratio
per SD 1.62) and C-reactive protein (hazard ratio 1.25) were
signiﬁcant independent predictors for incident AF. BNP improved
risk stratiﬁcation based on well-established clinical risk factors [16].
Concluding remarks
Taken together, prevalence of AF must be underestimated. In
order to ﬁnd more patients with AF, more frequent and longer
duration of ECG recording would be necessary. In addition,
biomarkers, especially BNP, would be helpful to detect asymp-
tomatic AF. Since AF is absolute arrhythmia and irregular pulse can
be found easily, all physicians should check pulse at every patient’s
visit prior to ECG recording. It appears to be the simplest and most
effective way to detect AF in general clinical practice. Early
detection of AF is the ﬁrst step to prevent cardiogenic stroke.
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